secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-PATH HOLDINGS, INC. (BPTH)
CIK:        0001133818
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0001558370-24-008844
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Path presents positive Phase 2 prexigebersen data at ASCO; 75% CR/CRh/CRi in newly diagnosed AML
--------------------------------------------------------------------------------

- Cohort 1 (newly diagnosed AML): 75% of evaluable patients (15/20) achieved CR/CRh/CRi; median age 75 yrs, adverse-risk or sAML.
- Cohort 2 (relapsed/refractory AML): 55% of evaluable patients (12/23) achieved CR/CRi/CRh; median age 63 yrs.
- Safety profile consistent with decitabine+venetoclax; common AEs: fatigue (72%), anemia (60%), neutropenia (49%).
- Bio-Path plans to continue enrollment up to 98 evaluable in Cohort 1 and 54 evaluable in Cohort 2.
- Data presented as oral presentation at ASCO 2024 by MD Anderson investigator; CEO highlights unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024008844/0001558370-24-008844-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133818/000155837024008844/bpth-20240603x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008844

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer